Metabolic · In Clinical Trials
Amycretin
No lawful US pathway
01 · Overview
Amycretin is a single-molecule (unimolecular) agonist of both the GLP-1 receptor and the amylin receptor, developed by Novo Nordisk for obesity in both oral and subcutaneous forms (PMID 40550229, PMID 40550231). GLP-1 receptor activation enhances satiety and glucose-dependent insulin secretion, while amylin receptor activation reduces food intake and slows gastric emptying.
Combining both activities in one molecule is intended to produce greater weight loss than either pathway alone.
02 · Research summary & key findings
In a first-in-human phase 1 trial of oral amycretin in people with overweight or obesity, adverse events were all mild or moderate and mostly gastrointestinal (PMID 40550229). In a phase 1b/2a trial of once-weekly subcutaneous amycretin, mean weight change was -9.7 percent at 20 weeks at the lowest maintenance dose and up to -24.3 percent at 36 weeks at the highest dose, versus roughly -1 to +2 percent with placebo (PMID 40550231). Gastrointestinal adverse events were frequent but mostly mild to moderate, and many participants withdrew for reasons unrelated to adverse events (PMID 40550231).
03 · Regulatory status
Amycretin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Amycretin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Amycretin is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial Lancet, 2025. PMID 40550229
- [2]Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study Lancet, 2025. PMID 40550231
Primary literature
- PubMed: "Amycretin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Amycretin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Amycretin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.